Login / Signup

Efficacy of Tocilizumab in COVID-19: Single-Center Experience.

Safak KayaSeyhmus Kavak
Published in: BioMed research international (2021)
Tocilizumab is still among the COVID-19 treatment options and appears to be effective. But the start time is important. In order to increase its effectiveness, it may be important to know a cut-off value of the laboratory findings required for the diagnosis of cytokine release syndrome. Further studies are needed for this.
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • rheumatoid arthritis patients
  • randomized controlled trial
  • respiratory syndrome coronavirus
  • case report
  • disease activity